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While overexpression of TGFα has been reported in human pancreatic ductal adenocarcino-
ma (PDAC), mice with overexpressed TGFα develop premalignant pancreatic acinar-to-
ductal metaplasia (ADM) but not PDAC. TGF-β signaling pathway is pivotal to the develop-
ment of PDAC and tissue fibrosis. Here we sought to investigate the interplay between TGFα
and TGF-β signaling in pancreatic tumorigenesis and fibrosis, namely via Smad4 inactivation.
Methods
TheMT-TGFαmouse was crossed with a new Smad4 conditional knock-out mouse
(Smad4flox/flox;p48-Cre or S4) to generate Smad4flox/flox;MT-TGFα;p48-Cre (STP). After
TGFα overexpression was induced with zinc sulfate water for eight months, the pancreata
of the STP,MT-TGFα, and S4mice were examined for tumor development and fibrotic re-
sponses. PanIN lesions and number of ducts were counted, and proliferation was measured
by Ki67 immunohistochemistry (IHC). Qualitative analysis of fibrosis was analyzed by Tri-
chrome Masson and Sirius Red staining, while vimentin was used for quantification. Expres-
sion analyses of fibrosis, pancreatitis, or desmoplasia associated markers (α-SMA, Shh,
COX-2,Muc6, Col1a1, and Ctgf) were performed by IHC and/or qRT-PCR.
Results
Our STPmice exhibited advanced ADM, increased fibrosis, increased numbers of PanIN le-
sions, overexpression of chronic pancreatitis-related marker Muc6, and elevated expres-
sion of desmoplasia-associated marker Col1A1, compared to theMT-TGFαmice. The
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inactivation of Smad4 in the exocrine compartment was responsible for both the enhanced
PanIN formation and fibrosis in the pancreas. The phenotype of the STPmice represents a
transient state from ADMs to PanINs, closely mimicking the interface area seen in human
chronic pancreatitis associated with PDAC.
Conclusion
We have documented a novel mouse model, the STPmice, which displayed histologic pre-
sentations reminiscent to those of human chronic pancreatitis with signs of early tumorigen-
esis. The STPmice could be a suitable animal model for interrogating the transition of
chronic pancreatitis to pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplasm of the pancreas
[1]. Despite the low incidence of 6–12 per 100,000 per year, PDAC is the fourth leading cause
of cancer deaths in the United States due to the lack of early detection methods and effective
treatments [2]. While the cell of origin remains to be clearly defined, it is proposed that pan-
creatic cancer can progress from acinar to ductal metaplasia (ADM) and is a result of the
combination of genetic events and extrinsic factors that produce tissue injury, such as the as-
sociated inflammatory damages observed during pancreatitis [3, 4]. Chronic pancreatitis is
characterized by fibroinflammatory changes of the pancreatic tissue and has been shown to
be a risk factor for pancreatic cancer [5]. Transforming growth factor-alpha (TGFα) is a
member of the epidermal growth factor (EGF) family of cytokines, which acts in autocrine
and paracrine fashions by binding to the EGF receptor to regulate cell proliferation, differen-
tiation, transformation, and migration [6]. Overexpression of TGFα has been reported in
transformed cells of many cancer types, including the acinar cells and ductal epithelium in
human pancreatic cancer [7, 8]. Transgenic mice expressing TGFα transgene under the con-
trol of zinc-inducible metallothionein (MT) promoter/enhancer or elastase promoter exhib-
ited progressive pancreatic fibrosis, loss of acinar cell mass, and development of extensive
tubular complexes, termed pseudoductular metaplasia [9, 10].
SMAD4, originally isolated from human chromosome 18q21.1, is a key intracellular mediator
of transcriptional responses to TGF-β. TGF-β plays a complicated, biphasic stage-specific role
in tumorigenesis by serving as a tumor-suppressor during early initiation, and yet promoting
tumor progression in late stages [11]. As a central effector of the TGF-β pathway, SMAD4 is be-
lieved to be a tumor-suppressor gene as evidenced by being biallelically inactivated in more than
50% of pancreatic carcinomas [12]. Smad4 deficiency can lead to rapid progression of pancreatic
tumors in the context of activated KrasG12D; however, Smad4 deficiency alone is incapable of ini-
tiating pancreatic tumorigenesis and dispensable for normal pancreas development [13–15].
In addition to its importance in tumorigenesis, TGF-β signaling has long been recognized to
induce extracellular matrix (ECM) synthesis and tissue fibrosis [16, 17]. While fibrotic disease
represents a large group of disorders for which there is no effective therapy, the precise contri-
bution of TGF-β or Smad4 to fibrotic disease is still unclear [16]. In the case of chronic pancre-
atitis, progressive fibrosis and destruction of the gland can result in exocrine and endocrine
insufficiency. It has been previously shown that loss of TGF-β signaling in fibroblasts results in
increased TGFα [18], therefore we set out to examine the possible synergetic effects of Smad4
loss and TGFα overexpression in vivo.
TGFα and Smad4 in Pancreatic Metaplasia and Fibrosis
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In the present study, we crossed theMT-TGFαmouse with a Smad4 conditional knock-out
mouse (SMAD4flox/flox;p48-Cre; hereafter S4), to generate SMAD4flox/flox;MT-TGFα;p48-Cre
(hereafter STP). We present evidence that more prominent ADM and advanced fibrosis were
observed in the STPmice than in theMT-TGFαmice. PanIN lesions, which were rarely de-
tected in theMT-TGFαmice, were a more common occurrence in the STPmice. These results
demonstrated that although Smad4 inactivation alone was not sufficient to induce phenotypic
changes, it could accerbate the pathological changes initiated by the overexpression of TGFα.
Overall, the STPmice displayed histologic presentations reminiscent to those of human chron-
ic pancreatitis transitioning to early tumorigenesis. This was confirmed by the upregulated ex-
pression of desmoplasia-associated Col1A1 and chronic pancreatitis-related Muc6 detected in
the STPmice [19], indicating that STPmice may be a suitable animal model for studying the
transition of chronic pancreatitis to pancreatic cancer.
Materials and Methods
Animals and treatments
To generate a conditional Smad4 knockout mouse line (Smad4flox/flox), exon 9 of the Smad4
gene was flanked by loxP sites (Fig. 1A). The details on the generation of the Smad4flox/flox
mouse line are described in the S1 Text. The resulting Smad4flox/flox and Smad4flox/flox;p48-Cre
mice were live-born and fertile as expected from previous similar publications [13–15].MT-
TGFα [9] and p48-Cremice were previously described [20].
Smad4flox/flox;MT-TGFα;p48-Cre (STP), Smad4flox/flox;p48-Cre (S4), and MT-TGFαmice
were treated with zinc sulfate (ZnSO4) water (25mM) for eight months and monitored for
Fig 1. Smad4 deficiency cooperates withMT-TGFα in the growth of fibrotic pancreata. (A). Targeting scheme of the Smad4flox/flox allele with the
introduction of two loxP sites flanking exon 9 of the DPC4/Smad4 gene. (B). Representative STPmouse at necropsy (pa: Pancreas; sto: Stomach; in:
Intestine) (left). A grossly normal pancreas from a S4 mouse and fibrotic pancreata fromMT-TGFα, and STPmice after 8-months of zinc sulfate treatment
(right).
doi:10.1371/journal.pone.0120851.g001
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significant weight loss, extreme weakness, or inactivity as a sign of illness. At the end of the in-
duction time mice were euthanized and tissues were formalin fixed and paraffin embedded. All
studies were conducted in compliance with the guidelines of and with the approval of the Insti-
tutional Animal Care and Use Committee (IACUC) of Columbia University Medical Center
(Protocol #AC-AAAF1457). Mice were genotyped by Transnetyx Inc. (Cordova, TN).
Histology and immunohistochemistry
Tissues were fixed in 10% formalin overnight and embedded in paraffin. All pancreata were rou-
tinely stained with Hematoxilin & Eosin (H&E) and analyzed by a pathologist (H.E.R.) for any
sign of pancreatic tumor development. Stromal proliferation and fibrosis in mice of 8 months of
age were qualitatively graded as: mild (1+), defined as surface area of cross section of pancreas
composed of<30% stromal; moderate (2+), stromal component comprises 30% to 60% of sur-
face area; strong (3+), stromal component comprises greater than 60% of surface area).
For immunohistochemistry (IHC), slides were deparaffinized in xylene and rehydrated se-
quentially in ethanol. Antigen retrieval was performed in 0.01M citrate buffer (pH 6.0) for 20
minutes in a microwave oven. Slides were quenched in peroxidase blocking reagent (Dako,
Carpinteria, CA) for 30 minutes to block endogenous peroxidase activity. Slides were then in-
cubated overnight at 4°C with primary antibodies diluted in antibody diluent buffer (Dako,
Carpinteria, CA). The Dako LSAB-System-HRP kit was employed for signal amplification. Fi-
nally, slides were counterstained with hematoxylin, dehydrated sequentially in ethanol, cleared
with xylenes, and mounted with Cytoseal 60 (Thermo Fished Scientific, Waltham, MA). The
primary antibodies and dilutions were: Smad4, 1:100 (Abcam, Cambridge, MA); CK19, 1:20
(TROMA3, Developmental Studies Hybridoma Bank at the University of Iowa, Iowa City,
Iowa); COX-2, 1:100 (cloneSP21, Thermo Scientific, Waltham, MA); Glucagon, 1:1000 (ab932,
Millipore, Billerica, MA); Insulin, 1:1000 (A0564, Dako, Carpinteria, CA); α-SMA, 1:200
(ab5694–100, Abcam, Cambridge, MA); Vimentin, 1:350 (ab92547, Abcam, Cambridge, MA),
Mucin 6, 1:200 (M-86, Santacruz, Santa Cruz, CA) and p-ERK, 1:500 (#4370, Cell Signaling
Technologies, Danvers, MA). Proliferation was assessed by IHC against Ki-67 (clone TEC-3,
Dako, Carpinteria, CA). All the antibodies were of rabbit origin except for CK19 (Rat), for
which 10 minutes incubation with polyclonal rabbit anti-rat immunoglobulins (E0468, Dako,
Carpinteria, CA) preceded the signal amplification step.
For double staining, the primary antibodies anti-amylase (1:2500) (Calbiochem, San Diego,
CA) and anti-CK19 (1:50) (TROMA3, Developmental Studies Hybridoma Bank at the Univer-
sity of Iowa, Iowa City, Iowa) were mixed together and the slides were incubated overnight at
room temperature. The slides were then incubated with biotinylated anti-rat secondary anti-
body for 30 min, followed by incubation with Dako Avidin-HRP for another 30 min. DAB sub-
strate (brown) was used for CK19 staining. The ImmPRESS-AP Polymer Anti-Rabbit IgG
(Vector Labs, MP-5401) was used for labeling the amylase antibody. The red substrate for alka-
line phosphatase (Vector Labs, SK-5100) was used for staining amylase protein. Nuclei were
stained with hematoxylin. All the procedures were performed according to the manufacturer’s
instructions. Fibrosis was analyzed by Trichrome Masson Staining (Sigma-Aldrich, St. Louis,
MO) and Sirius Red (Direct Red 80, Sigma-Aldrich, St. Louis, MO) following the manufactur-
er’s protocols. For Alcian blue staining, rehydrated paraffin sections were stained for 15 min-
utes at room temperature in a 3% solution of Alcian blue diluted in acetic acid.
Quantitative analysis of stromal proliferation and fibrosis was achieved by measuring the
areas positive for vimentin immunoreaction. Briefly, six random, non-overlapping, 200X im-
ages were collected from 4 mice per genotype. For each image positive vimentin area was nor-
malized to total area of each field using ImageJ 1.48g software (NIH, USA). Similar approach
TGFα and Smad4 in Pancreatic Metaplasia and Fibrosis
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was carried out to quantify the area occupied by mucinous lesions. Error bars represent means
± standard error of the mean (S.E.M.). PanIN lesions were classified according to histopatho-
logic criteria recommended in the literature [20, 21].
Images were captured with a Nikon Labophot-2 Microscope using the Nikon Imaging Soft-
ware NIS-Elements-F 2.20 (Melville, NY).
Immunoblot analysis
Pancreatic frozen tissues were homogenized using a sonicator in ice-cold RIPA buffer including
protease/phosphatase inhibitors (Roche Diagnosis, Indianapolis, IN). Samples were pre-boiled
for 5 min and diluted to the same concentration using Laemmli buffer 2x and then separated
using Novex 4–20% Tris-Glycine Gels (Invitrogen, Carlsbad, CA). Transfers were done onto a
PVDF membrane (Millipore, Temecula, CA). Membranes were pre-blocked with TBST—5%
Non-fat dry milk and then incubated with primary antibodies: Vimentin (ab92547, Abcam,
Cambridge, MA), Col1a1 (sc-8784-R, Santa Cruz Biotechnology, Santa Cruz, CA) and Beta-
actin (sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA). After washing with TBS-0.1%
tween-20, secondary antibodies (Cell signaling, Danvers, MA) were added and membranes in-
cubated for 1 hour.
Expression analysis
Tissues were preserved in RNAlater (Qiagen, Valencia, CA) at -20°C until RNA isolation. RNA
was isolated by RNeasy (Qiagen, Valencia, CA) purification and DNAse treatment, followed by
reverse transcription (SuperScript III Reverse transcriptase kit, Invitrogen; Carlsbad, CA) and
quantitative real-time PCR (Q-PCR), performed in ABI Prism 7500 Sequence Detector (Ap-
plied Biosystems, Foster City, CA) using Power SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA) and the following oligonucleotides: Col1a1 (Fwd 5’-
ACCTCAAGATGTGCCACTC-3’; Rvs 5’-TGCTCTCTCCAAACCAGAC-3’), α-SMA (Fwd 5’-
GACGCTGCTCCAGCTATGT-3’; Rvs 5’- AGTTGGTGATGATGCCGTGT-3’), Ctgf (Fwd 5’-
TGACTGCCCCTTCCCGAGAA-3’; Rvs 5’- TCTTCCAGTCGGTAGGCAGCTAGG- 3’),
muc4 (Fwd 5’- CTCCAAGAAATGTAGTGGCTTTCAG-3’; Rvs 5’- CACGGTCTTGGGCTG-
GAGTA-3’)Muc6 (Fwd 5’-GCCGAGCGTAAATGCAACAT-3’; Rvs 5’- CTCCAAGAAATG-
TAGTGGCTTTCAG-3’) Sonic Hedgehog (Fwd 5’- ACCGAGGGCTGGGATGAGGA-3’; Rvs
5’- ATTTGGCCGCCACGGAGTT-3’). Optimal primer concentrations were determined using
optimization protocols from Applied Biosystems SYBR Green PCRMaster Mix manual. Rela-
tive Quantification was performed and the expression levels were normalized to Rpl0 with the
fold-change calculated based on the ΔΔCt method relative to S4 mice.
Statistical analysis
Results were presented as the mean ± SEM. The Student’s t-test was used to compare data be-
tween groups. p-values less than 0.05 were considered to be statistically significant.
Results
Smad4 is efficiently deleted in STP and S4 mice
While the S4mice presented with normal pancreata, gross inspection of the STPmice at necrop-
sy revealed enlarged fibrotic pancreata with frequent cystic formation due to duct dilation simi-
lar to those found in theMT-TGFαmice [9, 10] (Fig. 1B). Body weight, pancreas to body weight
ratio, and survival were similar between the STP andMT-TGFαmice (data not shown). Tissue-
specific Cre-mediated rearrangement of the Smad4lox allele in the S4 and STPmice was
TGFα and Smad4 in Pancreatic Metaplasia and Fibrosis
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documented by allele-specific PCR genotyping (S1 Fig.) and further confirmed by Smad4 IHC,
demonstrating the generation of a null allele in the pancreas of the STP and S4mice but not in
theMT-TGFαmice (Fig. 2). STP and S4mice presented loss of Smad4 expression in the ductal
epithelium while positive expression was detected in the stroma (Fig. 2ii, vi), whereasMT-TGFα
mice maintained Smad4 expression in both ductal epithelium and stromal component (Fig. 2iv).
Smad4 deficiency in the pancreas cooperated with TGFα in promoting
the expansion of the epithelial compartment and ADM to PanIN
progression.
Mice with homozygous deletion of Smad4 in the pancreas showed no evidence of any gross an-
atomic or physiological abnormalities, and exhibited normal pancreatic cytoarchitecture
(Fig. 1B, Fig. 2i, & S2 Fig.). As previously reported, pancreata of theMT-TGFαmice underwent
a progressive histologic transformation, characterized by diffuse fibrosis and altered acinar cell
structure, ADM, ductal proliferation and dilatation [9, 10] (Fig. 2iii & Fig. 3A-i, iii). The STP
mice showed more pronounced interlobular fibrosis, tubular metaplasia, islands of proliferat-
ing cells within the tubules and ADM that involved progressive dilatation of the acinar lumen
(Fig. 2v & Fig. 3A-ii, iv). With the decrease in the height of acinar cells, we also observed a cu-
boidal epithelium morphologically simulating metaplastic ducts and/or PanIN-1 in the STP
mice (Fig. 3A-iv). Both theMT-TGFαmice and STPmice presented disruption of islet cells
due to ductal proliferation and increased fibrosis as shown (S2v-vii Fig., S2ix-xi Fig.). The di-
minished exocrine compartment observed was likely due to ADM as demonstrated by co-IHC
of amylase and CK19 (Fig. 3A-v, vi & S2iv, iii, xii Fig.).
Fig 2. Smad4 deficiency enhances TGFα-induced histological changes. The STPmice displayed similar but more pronounced architectural changes in
the pancreata than theMT-TGFαmice, while the no apparent change was detected in the pancreata of S4 mice. The loss of Smad4 expression in the ductal
epithelial cells was confirmed in the S4 and STPmice by IHC. Histological sections from 8-months of zinc sulfate treated S4 (panels i, ii),MT-TGFα (panels iii,
iv) and STP (panels v, vi) mice stained with H&E (panels i, iii, v); with antibodies to Smad4 (panels ii, iv, vi). Magnifications: panels 100x/200x; insets 400x.
doi:10.1371/journal.pone.0120851.g002
TGFα and Smad4 in Pancreatic Metaplasia and Fibrosis
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Malignant pancreatic tumors were not detected in any of the mice subjected to zinc sulfate
water treatment for up to 8 months. Both theMT-TGF-α and STPmodels showed increased
numbers of ductal structures (include both metaplastic ducts and/or PanIN-1 & -2) in compari-
son to the S4mice, but with no statistical difference between each other (Fig. 3B). Strikingly, the
number of PanIN-1 & -2 lesions was significantly higher in the STPmice compared to the
MT-TGFαmice (Fig. 3B;MT-TGFα: 1.8±0.6; STP: 11.7±2.8; Student’s t-test, p = 0.025). This
was supported by the increased positivity for Alcian blue, which is a marker of intestinal mucin,
in the STPmice when compared to theMT-TGFαmice (Fig. 3A; vii-viii and Fig. 3B;MT-TGFα:
1.2%±0.7; STP: 5.8%±0.7; Student’s t-test, p = 0.016). Analysis of proliferation within the meta-
plastic ductal epithelia in both models showed a significant increase in the fraction of ki67-posi-
tive cells in the STPmice when compared to theMT-TGFαmice (Fig. 4;MT-TGFα: 8.5%±0.7;
STP: 17.4%±1.0TGFα; Student’s t-test, p = 0.003). The pronounced epithelial reprogramming
resulted from ADM (Fig. 3A-v, vi) and the heightened ductal proliferation (Fig. 4) likely con-
tributed to the marked increase in the numbers of PanIN lesions in the STPmice.
Smad4 deficiency enhances TGFα-induced fibrosis
In addition to the changes in the epithelial cells, pancreata of the STPmice and theMT-TGFα
mice displayed progressive accumulation of fibrotic stroma and fibroblasts, demonstrated by in-
creased Trichrome staining, Sirius red staining (S3 Fig.) and vimentin immunoreactivity
(Fig. 5A). Qualitative analysis of relative stroma area assessed by a pathologist (H.E.R.) indicat-
ed augmented pancreatic fibrosis in the STPmice in comparison to theMT-TGFαmice, which
was confirmed by the quantitative analysis of the relative pancreatic area positive for vimentin
expressions by IHC (Fig. 5B;MT-TGFα: 56.7%±4.4; STP: 75.0%±5.8; Student’s t-test, p = 0.003)
and also byWestern blot analysis of vimentin expressions in the total protein extracts from
pancreata of the S4,MT-TGFα and STPmice (Fig. 5C).
Further IHC analysis and expression analysis were performed on the pancreata to interrogate
the potential Smad4-dependent molecular alterations in the neoplastic epithelium and in the
stroma compartment of the STPmice compared to theMT-TGFαmice. Activated pancreatic fi-
broblasts or stellate cells (PSCs) were detected in both models, exclusively in the areas surround-
ing the ductal lesions (surrounding the ADM in theMT-TGFαmice and the ADM and PanINs
in the STPmice) by α-SMA labeling. PSCs are activated through paracrine signals from neigh-
boring cells (acinar, ductal, endothelial and lymphocytes) and/or autocrine signals upon expo-
sure of the pancreas to ethanol, to its metabolites and to insults that generate reactive oxygen
species (ROS). Persistent activation of the PSCs is known to make an important contribution to
ECMmodulation and fibrogenesis [22] (S4A-i, iv Fig.). RNA expression analysis of α-SMA
showed higher levels in theMT-TGFα and STPmice than the S4mice, although with similar lev-
els in both models (S4B Fig.;MT-TGF-α: 180.9±1.2; STP: 198.3± 5.9 Student’s t-test, p = 0.0222
and 0.0209 respectively), which was consistent with the observed PSCs in both models. Shh is
known to contribute to the formation of desmoplasia in pancreatic cancer [23]. Here Shh was
frequently expressed in PanIN lesions of the STPmice, and also detected in the ADMs of both
the STP andMT-TGFαmice (S4A-ii, iv Fig.). Shh1 RNA expression was upregulated in the STP
mice compared to theMT-TGFαmice, although not significantly (Fig. 4B), probably because
upregulated Shh1 expression was detected in both ADM and PanINs (S4A-ii, iv Fig.). Both the
STP andMT-TGFαmodels presented significantly higher levels of Shh1 expressions than the S4
mice (S4B Fig.;MT-TGFα: 1222.8±601.2; STP: 3170.2±347.1; Student’s t-test, p = 0.0209 and
0.0222 respectively). COX-2 has a cell intrinsic role in pancreatic cancer development and is
also required for cancer stimulated PSC proliferation [24, 25] and its heightened expressions in
the ADM lesions of both models and in the PanIN lesions and stroma of the STPmice were
TGFα and Smad4 in Pancreatic Metaplasia and Fibrosis
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Fig 3. Significant increased number of PanIN lesions observed in the STPmice. (A) Pancreas specimens from 4 and 8-months zinc sulfate treatedMT-
TGFα (panels i, iii, v, vii) and STP (panels ii, iv, vi, viii) were H&E stained (panels i-iv), co-immunolabeled (co-IHC) with antibodies against cytokeratin-19
(brown) and amylase (pink) (panels v, vi), or Alcian blue stained (panels vii, viii).MT-TGFαmice display ductal proliferation with increased ADM at both 4 and
8 months of treatment (panels i, iii). STPmice showed progression from ADM to PanIN-1 & -2 lesions (panels ii, iv). Arrows indicate ADM lesions and plus
signs denote PanIN-1 lesions. The occurrence of ADMs in both models was demonstrated by co-IHC of Ck19 and amylase (panels v, vi). Alcian blue
indicated vastly increased mucin contents within ducts in the STPmice (panel viii) over theMT-TGFαmice (panel vii). (B) Morphometric analysis of pancreata
fromMT-TGFα and STPmice treated with 8-months of zinc sulfate. Four mice per genotype were analyzed with a minimum of five fields counted per mouse
(100x). (Upper panel): The graph depicts the average number of ducts per 200x field. There was no significant difference in the number of total ductal
structures counted in both models. (Middle panel): The graph depicts the average number of PanIN-1 & -2 lesions per 200x field. The STP mice exhibited
marked increase of PanIN-1 & -2 lesions than theMT-TGFαmice. (Lower panel): Percentage of Alcian blue positive area per 100x field was presented. The
increased PanIN lesions were consistent to the enhanced Alcian blue positivity in the STPmice. Values are presented as mean ±SEM. (Student’s t-test, ** p
< 0.05). Magnifications: panels 100X; insets 400x.
doi:10.1371/journal.pone.0120851.g003
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consistent with the observed PSC (S4A Fig.). Both the STP andMT-TGFαmice showed absent
and/or weak labeling for Muc4 andMuc5A; these two mucins are often associated with PDAC
development in humans [26–29] (data not shown).
Smad4 deficiency cooperates with TGFα in the upregulation of
molecular markers associated with pancreatitis and desmoplasia
The combination of TGFα overexpression and Smad4 deletion in the pancreas of the STPmice
presented a number of histologic similarities to human chronic pancreatitis, including in-
creased fibrosis and development of PanIN-1& -2 lesions (S5 Fig.). Therefore, we further as-
sessed the expression of molecular markers that are associated with chronic pancreatitis
(Muc6) or desmoplastic reaction (Ctgf1 and Col1A1). Given that mucin genes are highly con-
served between human and mice [30] and thatMUC6 has been reported aberrantly expressed
in human chronic pancreatitis [19, 27], we sought to analyze Muc6 expression levels in the STP
andMT-TGFαmice. Intriguingly, IHC analysis showed enhanced expression of Muc6 in the
lumen of the PanIN lesions in the STPmice when compared to theMT-TGFαmice (Fig. 6A).
Fig 4. Smad4 deficiency significantly enhancedMT-TGFα-induced epithelial expansion. Increased
number of proliferating ductal cells was observed in the STPmice over theMT-TGFαmice. (A) Ki-67
immunolabeling of pancreata fromMT-TGFα (panel i) and STP (panel ii) mice after 8-months of zinc sulfate
treatment. Arrows denote proliferating epithelial cells in evolving ADM and PanIN lesions. (B) The graph
presents the percentage of Ki-67-positive epithelial cells among the total number of metaplastic cells
counted. The table shows the percentage of Ki67-positve cells and in parentheses the total counts of Ki67-
positive cells over the total number of metaplastic cells counted from at least three independent mice per
genotype and ten 400X fields per mouse are shown. Values are presented as mean ±SE; Magnifications
panels i and ii, 400x. (Student’s t-test, * p< 0.05; ** p< 0.01)
doi:10.1371/journal.pone.0120851.g004
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Expression analysis ofMuc6mRNA levels showed that both genotypes overexpressedMuc6
when compared to S4mice. This expression was significantly higher in the STPmice than the
MT-TGFαmice (Fig. 6B;MT-TGFα: 146.3±1.3; STP: 5354.4±3.2; Student’s test, p = 0.0275), in-
dicating, that the STPmice resemble not only the fibrotic phenotype (S5 Fig.), but also the
overexpression of a molecular marker found in human chronic pancreatitis. Quantitative ex-
pression analysis revealed elevated levels of Ctgf1 in the pancreata of both STP andMT-TGFα
mice when compared to the S4mice (Fig. 6B;MT-TGFα: 102.3±4.0; STP: 153.0±35.3; Student’s
t-test, p = 0.0059 and 0.0037 respectively), although the differences between the STP andMT-
TGFαmice were not statistically significant (Fig. 6B). Expression analysis of Col1A1 showed el-
evated levels in pancreata of both the STP andMT-TGFαmice when compared to the S4mice
(Fig. 6B;MT-TGFα: 14.3±0.2; STP: 86.5±5.8; Student’s t-test, p = 0.0056 and 0.0068 respective-
ly). In addition, the STPmice also presented significantly higher expression levels of Col1a1
when compared to theMT-TGFαmice (Fig. 6B; Student’s t-test, p = 0.010). This was further
supported by Western blot analysis (Fig. 6C). Together, our data demonstrate that the STP
mice present the histologic and molecular signatures that mimic both human chronic pancrea-
titis and early signs of pancreatic tumorigenesis.
Fig 5. Aggravated pancreatic fibrosis promoted by Smad4 deficiency in the context of TGFα
overexpression. Enhanced fibrosis was observed in the STPmice as measured by vimentin expression. (A)
Pancreas specimens fromMT-TGFα (panel i) and STP (panel ii) treated with 8-months of zinc sulfate were
immunolabled with anti-vimentin antibody. Magnifications: panels 100x. (B) Morphometric analysis of
pancreata from the vimentin IHC. Four mice per genotype were analyzed with six fields counted per mouse.
The graph presents the relative stroma area per 200x field based on the vimentin immunoreaction. Values
are presented as mean ±SEM. Student’s t-test was employed; * p< 0.05; ** P< 0.01. (C) Vimentin protein
expressions in the total protein extracts from the pancreata of the S4,MT-TGFα, and STPmice were
analyzed byWestern blot. β-actin was used as the loading control.
doi:10.1371/journal.pone.0120851.g005
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Discussion
PDAC is the fourth leading cause of cancer death in the United States with a five-year survival
as low as 6% [2]. Similar to many other human diseases, mouse models provide an important
model system to better understand the molecular mechanism underlying pancreatic cancers.
The generation of GEMMs for pancreatic cancer essentially involves targeting a variety of
genes in certain pancreatic cell lineages to produce an array of neoplastic changes [31]. Never-
theless, despite the establishment of these GEMMs, no single animal model can provide
Fig 6. STPmice displayedmolecular signatures of human chronic pancreatitis and desmoplasia.
Significantly elevated Muc6 and Col1a1 expressions were detected in the STPmice. (A) IHC analysis of
Muc6 expression in the pancreata fromMT-TGFα (panel i) and STPmice (panel ii) treated with zinc sulfate for
8 months. Elevated expression of Muc6 was detected in evolving ADM and PanIN lesions of the STPmice.
Magnification panels i and ii, 200X. (B) The RNA expressions of chronic pancreatitis markerMuc 6 and
desmoplasia markersCtgf (Connective tissue growth factor-1) andCol1a1 (Collagen type XXI alpha 1) in the
S4,MT-TGFα, and STPmice were measured by qRT-PCR. The graphs present the relative expression of
each gene to the S4mice.Muc6 andCol1a1 were significantly upregulated in the STP mice compared to the
MT-TGFαmice. Values are presented as mean ±SEM; Student’s t-test was employed, * p< 0.05; **p>
0.01; *** P< 0.005. (C) Elevated Col1a1 protein expression in the STPmice was confirmed byWestern blot
analysis of the total protein extracts from the pancreata of the three different models.
doi:10.1371/journal.pone.0120851.g006
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complete understanding of this disease. Due to the complexity of PDAC biology, novel combi-
nations of models are needed [32].
In the present study, we characterized the STP mouse with inducible TGFα overexpression
and Smad4 knock-out in a pancreatic cell lineage-specific manner. As part of the process, we
first established the Smad4flox/flox;p48-Cre (S4) mouse in which the Smad4 expression was delet-
ed in the exocrine cells. The pancreas of the S4mouse displayed normal histology, which is
consistent with previous reports on Smad4flox/flox;Pdx1-Cremice (Fig. 2) [13–15]. In contrast,
the pancreas of aMT-TGFαmouse underwent progressive histologic transformation character-
ized by diffuse fibrosis, tubular metaplasia, ADM, focal PanIN-1 lesions, and islands of prolif-
erating cells within the tubules (Fig. 2). When compared withMT-TGFαmice, STPmice
presented significantly more advanced pancreatic fibrosis, increased foci of metaplastic ductal
epithelium, and significantly increased numbers of PanIN lesions (Figs. 2 & 3). In the STP
mice, there was also evidence of epithelial expansion as indicated by augmented percentage of
Ki-67-positive epithelial cells (Fig. 4). However, no pancreatic tumor was detected after pro-
longed TGFα induction beyond one year in both models. The inactivation of Smad4 likely pro-
moted ADM to PanIN progression in the STPmice by enhancing the TGFα signaling. It was
recently reported by Chen et al. that SMAD4 loss in human pancreatic cancer cell lines led to
increased expression of EGFR and the restoration of SMAD4 attenuated EGFR signaling [33].
Consistent to our hypothesis, we detected p-ERK expression in the ADM of theMT-TGFα and
the STPmice (S6ii-iv Fig.). Moreover, the pronounced p-ERK expression partially persisted as
ADM progressed to PanIN lesions in the STPmice (S6 iii, iv Fig.).
In addition to tumorigenesis, TGF-β is linked to matrix deposition by regulating ECM
genes [16]. TGF-β has been shown to contribute to the initiation of fibrotic response in vivo.
The inactivation of TGF-β signaling by the overexpression of a dominant negative TGF-β re-
ceptor II attenuated pancreatic fibrosis and synthesis of ECM proteins induced by repetitive
acute pancreatic injuries [17]. While Smad3 expression in fibroblasts has been shown to be es-
sential for the induction of matrix in skin [16, 34], as a downstream mediator of TGF-β signal-
ing, Smad4 has yet to be assigned a role in pancreatic fibrosis. In our STPmice, we
demonstrated that the loss of Smad4 expression not only promoted the development of PanIN
lesions but also led to aggravated fibrotic changes in comparison to theMT-TGFαmice
(Fig. 3). The accumulation of fibroblasts in the STPmice was demonstrated by increased
vimentin expression (Fig. 5). It is worth noting that activated pancreatic stellate cells (PSCs)
were detected by α-SMA staining exclusively in areas surrounding the ductal lesions and
PanIN lesions in both models (S4 Fig.), which supported the observations of preneoplastic de-
velopment in this model. This provides the first direct in vivo evidence that Smad4 inactivation
in the exocrine lineage would also enhance fibrotic responses (Fig. 3). Fibrosis is generally de-
fined as the accumulation of excessive amounts of ECM proteins in a tissue; in addition to aci-
nar atrophy, fatty replacement, chronic inflammation, and abnormal ducts, pancreatic fibrosis
is a constant histopathological hallmark of chronic pancreatitis [35]. In theMT-TGFα and STP
mice, the fibrotic responses were likely initiated by the TGFα expression, which activated the
Shh and COX-2 signaling in the stroma (S4 Fig.) and the RAS/MEK/ERK signaling pathway in
the ADM of both models and in the PanIN lesions of the STPmice (S6 Fig.). The observed in-
teractions between TGFα and TGF-β pathways in promoting pancreatic fibrosis here are sup-
ported by previous finding of increased TGFα in fibroblasts losing TGF-β signaling [18], and
by the observation of de novo loss of heterozygosity in Smad4 loci in TGFα overexpressing
mouse models [36]. The increased fibrotic tissues, activated PSC, and inflammatory pathways
observed in the STPmice might have resulted directly from the inactivation of Smad4 or a reac-
tive response to the heightened PanIN development, which cannot be distinguished currently
in this study.
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Chronic pancreatitis has also been shown to be a risk factor for pancreatic cancer, with the in-
cidence of pancreatic cancer 10 and 20 years after the diagnosis of chronic pancreatitis being
1.8% and 4.0%, respectively [35]. The exact mechanism linking chronic pancreatitis and pancreat-
ic cancer has not been completely defined [5, 37]. While only a small fraction of patients diag-
nosed with chronic pancreatitis will develop pancreatic cancer, there is no biomarker to predict
the cancer development or monitor those at risk. Therefore, novel accurate and sensitive tech-
niques are urgently needed to detect pancreatic cancer at an early stage from chronic pancreatitis
[38, 39]. Mucins belong to a family of large glycoproteins that form a physical barrier to protect
the epithelial cells from acid, proteases, microorganisms, and mechanical trauma. Alterations in
the expression, localization, or glycosylation of mucins have been associated with cancer develop-
ment, transformation, cancer cell growth, and immune surveillance [40]. While MUC1, MUC4,
and MUC5AC are the most differentially overexpressed mucins in human PDAC, the selective
increase of MUC6 expression was identified as a potential biomarker for human chronic pancrea-
titis when compared to normal pancreas and PDAC in an unbiased screen [19]. This finding was
corroborated on an independent report studying the expression of mucins in PDAC and chronic
pancreatitis [27]. MUC6 has been detected in developing pancreas and in small pancreatic ducts
in patients with cystic fibrosis and concomitant chronic pancreatitis, while its role in the patho-
physiology of pancreatitis remains unclear [41]. The STPmice displayed many of the characteris-
tics described for human chronic pancreatitis (S5 Fig.). The overexpression pattern of Muc6
suggests that our STPmice denote some molecular similarity with chronic pancreatitis, in addi-
tion to the fibrotic phenotype (Fig. 6). Consistent with the observed PanIN lesions in the STP
mice, overexpression of Ctgf and Col1a1, two biomarkers associated with desmoplasia in human
pancreatic cancer were also upregulated in the STPmice relative to theMT-TGFαmice (Fig. 6B).
Of the two markers, Col1a1 upregulation was statistically significant by qRT-PCR (Fig. 6B),
which was further confirmed byWestern blot analysis (Fig. 6C). The combination of pancreati-
tis-like histology and frequent ADM to PanIN progression in the STPmice may provide a unique
opportunity for interrogating the transition of chronic pancreatitis to pancreatic cancer.
In conclusion, we have established a novel mouse model, the STPmice, with inducible
TGFα expression and Smad4 inactivation. The observed advanced ADM, accelerated fibrosis,
and increased number of PanIN lesions in the STPmice represents a transient state from
ADMs to PanINs, which morphologically resembles human chronic pancreatitis associated
with PDAC. Compared with the current mouse models used for investigating pancreatic can-
cers, the STPmouse may provide a new opportunity of research in the chronic pancreatitis-
PDAC progression.
Supporting Information
S1 Fig. Smad4 conditional knock-out genotyping and recombination. A, Example of PCR
genotyping of the tail DNA of Smad4flox/flox and Smad4flox/+ mice. The primers used for geno-
typing were: Smad4Gen-F:5’-CCTGTTGTGACGTGGAGG-3’ and Smad4Gen-R:5’-atttggg-
cagcgtagcaat-3. B, Evidence of Cre-induced recombination in pancreata of Smad4flox/flox;
p48Cre. PCR amplification of genomic DNA yielded a product of 480 bp, the predicted size of
the product following recombination at the loxP sites flanking the entire exon 9 of the Smad4
gene. PCR amplification of pancreas DNA from Smad4flox/flox littermate failed to yield the re-
combinant product, indicating no genomic recombination in the absence of the pancreas-spe-
cific, p48-Cre expression. The primers used for recombination analysis were the following:
Smad4Del-F: 5’-ATCGAGGAATTAAGTCATTTTC-3 and Smad4Del-R: 5’-GATAGTT-
CAGTGATGCCCCT-3’.
(TIFF)
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S2 Fig. Histological characterization of STPmice.Histological sections from the pancreata of
S4 (panels i-iv),MT-TGFα (panels v-viii) and STP (panels ix-xii) mice after 8-months of zinc
sulfate treatment were immunolabled with antibodies to insulin (panels i, v, ix); glucagon (pan-
els ii, vi, x), amylase (panels iii, viii, xi), and cytokeratin-19 (panels iv, viii, xii). Magnifications:
panels 100x; inserts 200x.
(TIFF)
S3 Fig. Pronounced pancreatic fibrosis observed in bothMT-TGFα and STPmice. (A) Pan-
creas specimens fromMT-TGFα (panels i-ii) and STP (panels iii-iv) mice after 8-months of
zinc sulfate treatment were stained with Masson’s Trichrome (panels i, iii) and Sirius Red (pan-
els ii, iv). Magnifications: 200x.
(TIFF)
S4 Fig. Activated pancreatic stellate cells observed in both STPmice andMT-TGFαmice.
(A) Pancreatic specimens from 8-months zinc sulfate-treatedMT-TGFα (panels i-iii) and STP
(panels iv-vi) were immunolabeled with antibodies to α-SMA (panels i, iv), Sonic Hedgehog
(panels ii, v) and COX-2 (panels iii, vi). The arrows point to positive α-SMA expression in
blood vessel in the MT-TGFa mice (panel i) and myofibroblast-like cells in the STPmice
(panel iv), and COX-2 labeling in the stroma of STPmice (panel vi). The asterisks denote Cox-
2-positivity in PanIN lesions of the STPmice (panel vi). (B) Relative RNA expressions of
αSMA and Sonic Hedgehog in the pancreatic tissues of S4 (set as 1),MT-TGFα (αSMA:180.9
±1.2 and Shh:1222.8±601.1) and STP (αSMA:198.3±5.9 and Shh:3179.28±347.1) mice as ana-
lyzed by qRT-PCR; three mice per genotype. Values are presented as mean ±SEM relative to S4
mice. Magnifications: panels i, iii, iv and vi 200x; panels ii, v 100X; insets 400X. (Student’s t-
test,  p< 0.05).
(TIFF)
S5 Fig. STPmice develop features similar to human chronic pancreatitis (A). Representative
H&E staining of human PC showing increased fibrosis, ductal proliferation, PanIN-1 and de-
struction of normal pancreatic architecture. (B) Representative H&E staining of STP mouse
treated with Zinc Sulfate for 8-months showing similar features to human CP. ac: acinar cells;
: Ductal proliferation; +: PanIN-1. Magnification, 100X.
(TIFF)
S6 Fig. MAPK activation was detected in the ADM and PanIN lesions in the STPmice. Rep-
resentative pancreatic specimens from 8-months zinc sulfate-treated S4 (panel i),MT-TGFα
(panel ii) and STP (panels iii-iv) were immunolabeled with antibody to p-ERK. MAPK activa-
tion was detected in the normal ducts of the S4mice (panel i), ADM ofMT-TGFα and STP
mice (panels ii and iii), and in some PanIN lesions of the STPmice (panel iii, iv). Magnifica-
tion, 100X for panel iii and 200X for panels i, ii, & iv; insets 400X.
(TIFF)
S1 Text. Construction of the conditional Smad4 targeting vector.
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